Executive Director, Analytics & Insights (NSCLC)

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Vice President, US Analytics & Insights, this role will serve as the analytics and insights leader dedicated to the Lung franchise, supporting launch planning and commercialization readiness for lung cancer assets. This individual will play a critical role in shaping franchise strategy through data-driven insights, while closely collaborating with forecasting, commercial, medical, and market access partners. This leader will operate as a player/coach, balancing hands-on analytical leadership with team development, and will be expected to personally contribute to high-priority strategic analyses while building and scaling a high-performing team. Candidates should bring deep oncology expertise, strong leadership capabilities, and a track record of translating complex data into actionable business insights within a fast-growing organization. This position is based out of our headquarters in Redwood City, CA. Responsibilities include: Serve as the franchise lead for Analytics & Insights for Lung, ensuring readiness to support successful launch planning, commercialization, and performance tracking in the US market. Lead generation of strategic insights from market research and advanced analytics to inform critical business decisions and franchise strategy. Operate as a player/coach, directly conducting and guiding critical analyses while mentoring team members and establishing best practices across the function. Partner closely with forecasting, finance, and portfolio strategy teams to provide key inputs, assumptions, and insights that inform forecast development (note: this role does not own forecasting). Collaborate with global insights & analytics, commercial, medical affairs, and market access teams to define business questions, shape research objectives, and understand evolving market dynamics in lung cancer. Translate complex datasets into clear, compelling insights and recommendations, and effectively communicate to senior leadership and cross-functional stakeholders. Oversee the design and execution of primary and secondary market research, including vendor selection and management, ensuring application of best practices and fit-for-purpose methodologies. Partner with Marketing, Sales, Market Access, and Information Systems to: Define key performance indicators (KPIs) Oversee the development of dashboards and reporting infrastructure Enable data-driven performance monitoring and decision-making Serve as a strategic thought partner to franchise leadership, identifying key business drivers, risks, and opportunities. Drive adoption of innovative analytics approaches, including artificial intelligence, advanced analytics, competitive intelligence, and emerging data sources. Build, lead, and develop a high-performing team supporting the Lung franchise. Required Skills, Experience and Education: Advanced degree (PhD, PharmD, MD, MBA, or equivalent) in a scientific or business discipline. 12+ years of relevant experience in biotech, pharmaceutical, or consulting environments, consistent with Executive Director-level expectations at RevMed. Deep experience in oncology, with strong preference for lung cancer expertise. Demonstrated success suppo